Avutometinib and Defactinib
Phase II of Avutometinib (VS-6766) and Defactinib In RAF Dimer-Driven RAI-Refractory Differentiated and Anaplastic Thyroid Cancer Patients
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2
- Enrollment
- 30 patients (estimated)
- Sponsors
- Memorial Sloan Kettering Cancer Center
- Collaborators
- Verastem, Inc.
- Tags
- MEK Inhibitor
- Trial Type
- Treatment
- Last Update
- 6 days ago
- SparkCures ID
- 2005
- NCT Identifier
- NCT06007924
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.